Tonapofylline

Drug Profile

Tonapofylline

Alternative Names: Adentri; BG-9928

Latest Information Update: 16 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CV Therapeutics
  • Developer Biogen Idec
  • Class Heart failure therapies; Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute heart failure; Chronic heart failure

Most Recent Events

  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
  • 22 Aug 2008 Phase-III clinical trials in Acute heart failure in World (IV)
  • 16 Aug 2007 Final results from a phase II clinical trial in Chronic heart failure added to the Heart Failure therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top